CeQur Simplicity

CeQur Simplicity

An Insulin Patch for Mealtimes Tailored to Match Your Lifestyle.

CeQur Simplicity

CeQur Simplicity brings a host of benefits to those managing diabetes, making the experience more comfortable and convenient. With fewer painful injections, it minimizes the hassle at mealtime, providing an easier alternative to traditional pens. The discreet dosing feature ensures privacy, while the device’s thin and lightweight design adds to the overall convenience.

Beyond the ease of use, CeQur Simplicity contributes to improved glucose control, encouraging adherence to treatment plans and resulting in better time spent within the target glucose range. It stands as a simple yet effective solution for individuals seeking a more user-friendly approach to insulin administration.

Contact us to learn more!

Talk to a physician to see if CeQur Simplicity™ is right for you.

CeQur Simplicity is covered on most commercial and Medicare Part D insurance plans as a pharmacy benefit.

Can the CeQur Simplicity patch be refilled or reused?

The CeQur Simplicity wearable insulin patch is designed for single use only, and cannot be reused due to an increased risk of infection, malfunctions, and/or incorrect insulin delivery. It’s not possible to refill an empty insulin reservoir in the patch.

Does the CeQur Simplicity patch come preloaded with insulin

Insulin is provided separately. You will need to fill the patch with your rapid-acting insulin

Who can use the CeQur Simplicity wearable insulin patch?

The patch is for people with type 1 or type 2 diabetes who require mealtime insulin.

Is CeQur Simplicity only for adults?

Yes, CeQur Simplicity is labeled for use in adults over the age of 21 who have been diagnosed with diabetes.

*Labeled for use with Humalog® U-100 and Novolo® U-100. Insulin sold separately. Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.

† For eligible, commercially insured patients. These offers are not valid for use by cash-paying patients or patients enrolled in Medicare, Medicaid, and TRICARE or other federal or state programs. Not valid where prohibited by law. Offers are subject to quantity limitations and maximum benefit amounts per fill apply. CeQur® reserves the right to rescind, revoke, or amend this offer without notice.

1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.

2. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.

3. Dreon D, Hannon T, Cross B, Carter B, Mercer N, Nguyen J, Tran A , Melendez P, Morales N, Nelson J, Tan M. 2018. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. Journal of Diabetes Science and Technology. 12(4):817-827.

4. Bergenstal RM, Johnson ML, Aroda VR, et al. Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. J Diabetes Sci Technol. 2022;16(5):1167-1173.